Loading...
Market
Who will be the primary target demographic for Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Adolescents • 25%
Adults • 25%
Elderly • 25%
Pregnant women • 25%
Official reports or studies published by health organizations or pharmaceutical companies
Story
Lenacapavir: New Injectable HIV Drug Offers 96-100% Efficacy with Twice-Yearly Dosing, Recognized as Scientific Breakthrough
Dec 30, 2024, 01:30 PM
A new injectable antiretroviral drug, Lenacapavir, has been recognized as a potential breakthrough in the fight against HIV and AIDS. According to reports, it boasts an efficacy rate of 96-100% and offers a twice-yearly dosing schedule, which could significantly enhance treatment accessibility and adherence. This innovation has been highlighted by the journal 'Science' as a scientific breakthrough of the year, with the potential to curb new HIV infections globally. Discussions around its availability and implementation are ongoing, as stakeholders consider the implications of this advancement in HIV prevention and treatment.
View original story
Similar markets
Adolescent girls • 25%
Other • 25%
General adult population • 25%
Gender-diverse individuals • 25%
North America • 25%
Africa • 25%
Europe • 25%
Asia • 25%
South America • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
Other • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
20% to 40% • 25%
76% to 99% • 25%
100% or more • 25%
Less than 50% • 25%
50% to 75% • 25%
UNAIDS • 25%
WHO • 25%
Global Fund • 25%
PEPFAR • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Reduction by 5% to 10% • 25%
Reduction by less than 5% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
Southeast Asia • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Latin America • 25%
Latin America • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%